vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and CaliberCos Inc. (CWD). Click either name above to swap in a different company.
Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $4.1M, roughly 2.0× CaliberCos Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -766.0%, a 577.7% gap on every dollar of revenue. On growth, CaliberCos Inc. posted the faster year-over-year revenue change (-52.5% vs -79.3%). Over the past eight quarters, Arcellx, Inc.'s revenue compounded faster (-24.6% CAGR vs -57.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
ACLX vs CWD — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $4.1M |
| Net Profit | $-62.3M | $-7.7M |
| Gross Margin | — | — |
| Operating Margin | -847.6% | -196.6% |
| Net Margin | -766.0% | -188.3% |
| Revenue YoY | -79.3% | -52.5% |
| Net Profit YoY | -765.1% | 32.2% |
| EPS (diluted) | $-1.13 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | $8.1M | $7.3M | ||
| Q4 24 | $15.3M | $8.7M | ||
| Q3 24 | $26.0M | $11.3M | ||
| Q2 24 | $27.4M | $8.2M | ||
| Q1 24 | $39.3M | $23.0M |
| Q4 25 | — | $-7.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | $-62.3M | $-4.4M | ||
| Q4 24 | $-47.1M | $-11.4M | ||
| Q3 24 | $-25.9M | $146.0K | ||
| Q2 24 | $-27.2M | $-4.7M | ||
| Q1 24 | $-7.2M | $-3.8M |
| Q4 25 | — | -196.6% | ||
| Q3 25 | — | -129.6% | ||
| Q2 25 | — | -112.4% | ||
| Q1 25 | -847.6% | -62.7% | ||
| Q4 24 | -348.2% | -236.8% | ||
| Q3 24 | -129.1% | 0.0% | ||
| Q2 24 | -127.8% | -65.0% | ||
| Q1 24 | -40.3% | -22.9% |
| Q4 25 | — | -188.3% | ||
| Q3 25 | — | -120.2% | ||
| Q2 25 | — | -104.5% | ||
| Q1 25 | -766.0% | -60.7% | ||
| Q4 24 | -308.4% | -247.6% | ||
| Q3 24 | -99.4% | 1.3% | ||
| Q2 24 | -99.3% | -57.8% | ||
| Q1 24 | -18.3% | -16.6% |
| Q4 25 | — | $1.95 | ||
| Q3 25 | — | $-1.65 | ||
| Q2 25 | — | $-4.15 | ||
| Q1 25 | $-1.13 | $-3.85 | ||
| Q4 24 | $-0.87 | $-10.15 | ||
| Q3 24 | $-0.48 | $0.12 | ||
| Q2 24 | $-0.51 | $-4.34 | ||
| Q1 24 | $-0.14 | $-3.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $1.3M |
| Total Assets | $648.1M | $135.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $683.0K | ||
| Q1 25 | $543.3M | $1.6M | ||
| Q4 24 | $587.4M | $2.3M | ||
| Q3 24 | $574.3M | $1.6M | ||
| Q2 24 | $516.7M | $1.8M | ||
| Q1 24 | $573.9M | $2.1M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-19.9M | ||
| Q1 25 | $416.9M | $-15.8M | ||
| Q4 24 | $454.8M | $-12.6M | ||
| Q3 24 | $483.0M | $-3.8M | ||
| Q2 24 | $487.2M | $-4.7M | ||
| Q1 24 | $496.6M | $-745.0K |
| Q4 25 | — | $135.4M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | $648.1M | $103.6M | ||
| Q4 24 | $711.3M | $105.5M | ||
| Q3 24 | $764.9M | $158.6M | ||
| Q2 24 | $734.3M | $195.2M | ||
| Q1 24 | $779.7M | $201.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-12.1M |
| Free Cash FlowOCF − Capex | $-63.9M | — |
| FCF MarginFCF / Revenue | -786.4% | — |
| Capex IntensityCapex / Revenue | 9.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-12.1M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | $-63.1M | $-1.7M | ||
| Q4 24 | $-46.0M | $555.0K | ||
| Q3 24 | $30.7M | $-74.0K | ||
| Q2 24 | $-36.2M | $1.4M | ||
| Q1 24 | $-31.9M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
